{"entity":{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","aka":["OV","TCGA-OV","ovarian serous cystadenocarcinoma (TCGA OV cohort)","Fallopian Tube Cancer","Primary Peritoneal Cancer"],"tldr":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease.","summary":"Ovarian cancer is a group of diseases (~320,000 new cases a year) dominated by high-grade serous carcinoma, which arises in the fallopian tube, is almost always TP53-mutant, and is diagnosed at stage III-IV in three-quarters of women because there is no symptom or screening test that catches it early. Roughly half of high-grade serous tumours have homologous recombination deficiency, including ~20% with germline or somatic BRCA1/2 mutations. Low-grade serous, endometrioid, clear-cell, and mucinous carcinomas are biologically distinct and respond differently to treatment.\n\nThe standard of care is maximal cytoreductive surgery (primary or interval, after neoadjuvant carboplatin-paclitaxel), sometimes with HIPEC, followed by maintenance therapy chosen by biomarker: olaparib for BRCA-mutated disease (SOLO-1, 7-year OS 67% vs 47%), olaparib plus bevacizumab for HRD-positive disease (PAOLA-1), niraparib for the rest with declining enthusiasm after PRIMA showed no survival gain. Platinum-sensitive relapse is treated with platinum doublets and secondary surgery in selected patients (DESKTOP III); PARP inhibitors are re-used less since later-line safety signals. Platinum-resistant disease, historically the hardest setting, now has three new options with survival benefit: mirvetuximab soravtansine for FRα-high tumours (MIRASOL), relacorilant plus nab-paclitaxel (ROSELLA, approved 2026), and pembrolizumab plus weekly paclitaxel for PD-L1-positive tumours (KEYNOTE-B96, approved February 2026, the first immunotherapy in ovarian cancer). Low-grade serous carcinoma gained its first dedicated therapy in avutometinib plus defactinib (2025).\n\nWhat comes next: folate-receptor ADCs that work regardless of expression level (rinatabart sesutecan, luveltamab tazevibulin), a CDH6 ADC (raludotatug deruxtecan) in phase 3, ATR and WEE1 inhibitors for PARP-resistant disease, and prevention by opportunistic salpingectomy now that the tubal origin is accepted. Screening remains unsolved after UKCTOCS; multi-cancer blood tests are the only live hope.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Ovarian_cancer","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Ovarian_cancer"}],"tags":["gyn","spike"],"related":["parp-plus-bevacizumab","hipec-at-interval-surgery","caution-pd1-first-line-ovarian","adc-generations","ovarian-cancer-research-alliance","paediatric-germ-cell-tumours","idea-targeting-aneuploidy"],"cancers":[],"sections":[],"technologies":["parp-inhibitor","adc","hipec","hrd-testing","synthetic-lethality-approaches","mced","risk-reducing-salpingectomy","germline-testing","ultrasound","robotic-surgery"],"targets":["brca","parp","folr1","cdh6","wee1","atr","tp53","mesothelin","cldn6","kras","vegf","pdl1","pd1"],"drugs":["thiotepa","amifostine","talc-sclerosant","catumaxomab"],"companies":["nanjing-leads-biolabs","bioinvent-international","haihe-biopharma","shenzhen-ionova-life-sciences","scancell","astrazeneca","merck","gsk","abbvie","corcept","verastem","genmab","sutro-biopharma","daiichi-sankyo","roche-genentech"],"institutions":[],"pathways":["ddr","p53-cell-cycle"],"terms":["ca-125","lgsoc","hgsoc","cps"],"trials":["nct04498117","nct06394492","nct06834672","nct06855069","nct07214779","nct07546500","nct05281471","nct04169997","nct07218809","nct07213804","nct04921527","nct03949283","nct07109414","nct06828354","nct05445778","nct04884360","nct07219238","nct07318558","nct06994195","nct06824467","nct06072781","nct05804370","nct07604766","nct06819007","nct04421963","nct06619236","nct07225270","nct06915025","nct07564141","nct01874353","nct03602859","nct07286266"],"people":["robert-coleman"],"bottlenecks":[],"keyPapers":["paper-brca-risk-reducing-surgery-jama-2010"],"journals":["international-journal-of-gynecological-cancer","journal-of-gynecologic-oncology"],"dependsOn":[],"notes":[],"group":"gynaecologic","burden":"Ovarian cancer accounts for ~320,000 cases per year worldwide. PARP-inhibitor maintenance has turned BRCA-mutated disease into one where two-thirds of women are alive at seven years, and three new treatments that extend life arrived for platinum-resistant disease in three years. Because most cases are found at stage III-IV, it remains the gynaecologic cancer with the lowest survival: 5-year survival ~50% overall and under 30% for stage IV; ~200,000 deaths per year.","subtypes":["High-grade serous carcinoma (~70%; TP53-mutant, tubal origin)","Low-grade serous carcinoma (~5%; KRAS/BRAF, ER+, chemoresistant)","Endometrioid carcinoma (~10%; often with endometriosis; CTNNB1, PTEN, MMR)","Clear-cell carcinoma (~10%; ARID1A, PIK3CA; platinum-resistant; higher in East Asia)","Mucinous carcinoma (~3%; KRAS, HER2 amplification; often gastrointestinal-like)","Carcinosarcoma and other rare types","Germ-cell and sex-cord stromal tumours (young women; highly curable)"],"biomarkers":["BRCA1/2 (germline and somatic)","HRD (myChoice)","FRα IHC","CDH6","CA-125","PD-L1","Germline and somatic BRCA1/2","HRD genomic instability score (myChoice CDx, FoundationOne)","Folate receptor alpha IHC (≥75% of cells at 2+ for mirvetuximab)","PD-L1 CPS ≥1 (pembrolizumab, KEYNOTE-B96)","KRAS/BRAF/NRAS (low-grade serous)","CA-125 and HE4 (monitoring, ROMA index)","Platinum-free interval (defines sensitive vs resistant)","MMR/MSI (endometrioid, clear-cell)","HER2 (mucinous, some clear-cell)"],"standardOfCare":[{"setting":"Newly diagnosed","approach":"Surgery + platinum-taxane ± bevacizumab ± HIPEC; PARP maintenance by HRD status.","refs":["carboplatin","paclitaxel","hipec","olaparib","niraparib"],"guideline":{"version":"NCCN Guidelines: Ovarian Cancer","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453"}},{"setting":"Platinum-sensitive relapse","approach":"Platinum doublet + PARP maintenance; secondary cytoreduction in selected cases.","refs":[],"guideline":{"version":"NCCN Guidelines: Ovarian Cancer","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453"}},{"setting":"Platinum-resistant","approach":"Mirvetuximab (FRα-high), relacorilant + nab-paclitaxel, pembrolizumab (PD-L1+), single-agent chemotherapy.","refs":["mirvetuximab-soravtansine","relacorilant","pembrolizumab"],"guideline":{"esmoMcbs":"2 (SORAYA mirvetuximab, single-arm)","version":"NCCN Guidelines: Ovarian Cancer","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11163648/"}},{"setting":"Prevention and risk","approach":"Germline testing for all patients; risk-reducing salpingo-oophorectomy for BRCA carriers (age 35-45); opportunistic salpingectomy at pelvic surgery for average-risk women; oral contraceptives reduce risk. No population screening (UKCTOCS negative).","refs":["germline-testing","risk-reducing-salpingectomy","chemoprevention","ukctocs"],"guideline":{"nccn":"Genetic/Familial High-Risk Assessment v2.2026","url":"https://www.nccn.org/guidelines/category_2"}},{"setting":"Newly diagnosed stage I-II","approach":"Complete surgical staging; adjuvant carboplatin-paclitaxel for high-grade or stage IC-II disease; observation for low-risk stage IA-IB grade 1-2.","refs":["carboplatin","paclitaxel","robotic-surgery"],"guideline":{"nccn":"1"}},{"setting":"Newly diagnosed stage III-IV: surgery and chemotherapy","approach":"Primary debulking if complete resection is feasible, else 3 cycles neoadjuvant carboplatin-paclitaxel then interval debulking (with HIPEC in stage III, OVHIPEC-1) and 3 more cycles; add bevacizumab for high-risk or residual disease.","refs":["carboplatin","paclitaxel","hipec","ovhipec-1","bevacizumab","gog-0218-icon7"],"guideline":{"nccn":"1 (chemotherapy); 2A (HIPEC)"}},{"setting":"First-line maintenance, BRCA-mutated","approach":"Olaparib 2 years (SOLO-1) or olaparib + bevacizumab (PAOLA-1) or niraparib 3 years (PRIMA).","refs":["olaparib","solo-1","paola-1","niraparib","prima"],"guideline":{"nccn":"1","esmoMcbs":"A","url":"https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-gynaecological-cancers/"}},{"setting":"First-line maintenance, HRD-positive BRCA-wild-type","approach":"Olaparib + bevacizumab (PAOLA-1, OS benefit) or niraparib (PRIMA, PFS only).","refs":["olaparib","bevacizumab","paola-1","niraparib","hrd-testing","parp-plus-bevacizumab"],"guideline":{"nccn":"1"}},{"setting":"First-line maintenance, HRD-negative","approach":"Bevacizumab continuation if started; niraparib is an option with small PFS benefit and no OS benefit (PRIMA); observation is reasonable.","refs":["bevacizumab","niraparib","prima"],"guideline":{"nccn":"2A"}},{"setting":"Platinum-sensitive relapse (interval >6 months)","approach":"Secondary cytoreduction if AGO-score positive (DESKTOP III); platinum doublet (carboplatin with PLD, paclitaxel, or gemcitabine) ± bevacizumab; PARP maintenance if PARP-naive and BRCA/HRD-positive.","refs":["desktop-iii","carboplatin","pegylated-liposomal-doxorubicin","bevacizumab","olaparib","niraparib","rucaparib"],"guideline":{"nccn":"1 (surgery in selected); 2A"}},{"setting":"Platinum-resistant relapse, FRα-high","approach":"Mirvetuximab soravtansine (MIRASOL, OS benefit) with ophthalmic prophylaxis.","refs":["mirvetuximab-soravtansine","mirasol","folr1"],"guideline":{"nccn":"1","esmoMcbs":"4"}},{"setting":"Platinum-resistant relapse, PD-L1 CPS ≥1","approach":"Pembrolizumab + weekly paclitaxel ± bevacizumab (KEYNOTE-B96, approved Feb 2026).","refs":["pembrolizumab","paclitaxel","bevacizumab","keynote-b96"],"guideline":{"nccn":"1 (2026 update)"}},{"setting":"Platinum-resistant relapse, other","approach":"Relacorilant + nab-paclitaxel (ROSELLA, approved 2026); single-agent weekly paclitaxel, PLD, or topotecan ± bevacizumab (AURELIA); clinical trials of FRα and CDH6 ADCs.","refs":["relacorilant","rosella","pegylated-liposomal-doxorubicin","bevacizumab","rinatabart-sesutecan","raludotatug-deruxtecan","aurelia"],"guideline":{"nccn":"2A"}},{"setting":"Low-grade serous carcinoma","approach":"Surgery; endocrine maintenance (letrozole) after chemotherapy or instead of it; at recurrence, avutometinib + defactinib if KRAS-mutated (2025), trametinib, or endocrine therapy.","refs":["letrozole","avutometinib-defactinib","ramp-201","lgsoc"],"guideline":{"nccn":"2A"}},{"setting":"Rare histologies","approach":"Clear-cell: platinum-based therapy, trials of immunotherapy and ARID1A-directed agents; mucinous: consider GI regimens and HER2 testing; germ-cell: BEP chemotherapy with >90% cure.","refs":["platinum","checkpoint-inhibitor"]}],"stateOfArt":["PARP maintenance with 7-year OS benefit in BRCA (SOLO-1).","First ADC (mirvetuximab) with OS benefit.","Biomarker-directed maintenance after first-line chemotherapy: olaparib for BRCA (7-year OS 67% vs 47%), olaparib + bevacizumab for HRD-positive disease.","Three new options with overall survival benefit in platinum-resistant disease within three years: mirvetuximab (FRα-high), relacorilant + nab-paclitaxel, and pembrolizumab + paclitaxel (PD-L1-positive, first immunotherapy approval in ovarian cancer, February 2026).","First treatment designed for low-grade serous carcinoma (avutometinib + defactinib, May 2025).","Surgery is evidence-based at both ends: HIPEC at interval debulking adds ~12 months of survival; selected secondary cytoreduction at relapse adds ~8 months.","Prevention by opportunistic salpingectomy is now routine policy in several countries because the tubal origin of high-grade serous cancer is accepted.","Germline and HRD testing at diagnosis is standard and changes treatment for roughly half of patients."],"history":[{"year":1976,"title":"Cisplatin transforms ovarian cancer chemotherapy","note":"First platinum responses in refractory disease; carboplatin follows in the 1980s.","refs":[]},{"year":1994,"title":"BRCA1 cloned; hereditary ovarian cancer explained","note":"BRCA2 in 1995; germline testing enters clinical practice over the next decade.","refs":["brca"]},{"year":1996,"title":"Paclitaxel-cisplatin standard","refs":[]},{"year":1996,"title":"Paclitaxel-cisplatin becomes standard (GOG-111)","refs":["paclitaxel","platinum"]},{"year":2005,"title":"Synthetic lethality of PARP inhibition in BRCA-deficient cells","note":"Farmer and Bryant papers in Nature set up the PARP inhibitor era.","refs":["parp","synthetic-lethality"]},{"year":2007,"title":"Fallopian tube identified as origin of high-grade serous cancer","note":"Serous tubal intraepithelial carcinoma described in BRCA carriers' prophylactic specimens; leads to salpingectomy-based prevention.","refs":["hgsoc","risk-reducing-salpingectomy"]},{"year":2011,"title":"Bevacizumab improves PFS (GOG-0218, ICON7)","refs":["gog-0218-icon7","bevacizumab"]},{"year":2014,"title":"Olaparib: first PARP inhibitor","refs":["olaparib"]},{"year":2014,"title":"Olaparib: first PARP inhibitor approved","note":"For germline BRCA-mutated ovarian cancer after three lines.","refs":["olaparib"]},{"year":2018,"title":"SOLO-1 and OVHIPEC-1","note":"Two years of first-line olaparib maintenance (PFS HR 0.30) and HIPEC at interval surgery (OS +12 months) both reported.","refs":["solo-1","ovhipec-1"]},{"year":2019,"title":"PARP maintenance extends beyond BRCA","note":"PRIMA (niraparib, all comers) and PAOLA-1 (olaparib + bevacizumab, HRD-positive).","refs":["prima","paola-1"]},{"year":2021,"title":"UKCTOCS: screening does not save lives; DESKTOP III: selected surgery at relapse does","refs":["ukctocs","desktop-iii"]},{"year":2022,"title":"Mirvetuximab: first ovarian ADC","refs":["mirvetuximab-soravtansine"]},{"year":2022,"title":"Mirvetuximab soravtansine: first ovarian ADC","note":"Accelerated approval; full approval after MIRASOL OS benefit in 2024.","refs":["mirvetuximab-soravtansine","mirasol"]},{"year":2023,"title":"SOLO-1 7-year OS benefit; PARP later-line labels narrowed","note":"First-line maintenance benefit confirmed while later-line PARP use retreats after OS imbalances (ARIEL4, SOLO3).","refs":["solo-1","rucaparib"]},{"year":2025,"title":"First LGSOC therapy (avutometinib + defactinib); ROSELLA and KEYNOTE-B96 positive","refs":["avutometinib-defactinib","ramp-201","rosella","keynote-b96"]},{"year":2026,"title":"Relacorilant and pembrolizumab approved in platinum-resistant disease","refs":["relacorilant"]},{"year":2026,"title":"Relacorilant and pembrolizumab approved in platinum-resistant disease","note":"First immunotherapy approval in ovarian cancer (February 2026).","refs":["relacorilant","pembrolizumab","keynote-b96"]}],"pipeline":["raludotatug-deruxtecan","puxitatug-samrotecan","parp-pet","galleri","pf-08634404","in10018","ipatasertib","saruparib","oregovomab","hlx43","shr-a1921","ibi354","gotistobart","hs-20089","incb123667","azenosertib","olvimulogene-nanivacirepvec","imp4927","azd5335","sofetabart-mipitecan","chiauranib","avzo-021","xnw27011","jk08","palacaparib","lorigerlimab","utomilumab","azd8421","tilt-123","pamiparib","cyh33","vudalimab","upifitamab-rilsodotin","theo-260","vb15010","nuv-1511","rinatabart-sesutecan","rainfol-01","luveltamab-tazevibulin","rejoice-ovarian01","avutometinib-defactinib","wee1","atr","risk-reducing-salpingectomy","idea-fra-adc-sequencing-ovarian","idea-ctdna-guided-parp-duration"],"openProblems":["No effective screening.","PARP resistance via BRCA reversion.","Platinum-resistant disease is the hardest setting; three drugs with survival benefit arrived in 2023-26 and each adds months, so combining and sequencing them is the next step.","Screening is unsolved: the UKCTOCS trial found no mortality reduction, so three-quarters of patients are still diagnosed at stage III-IV; opportunistic salpingectomy and multi-cancer blood tests are the live routes.","Platinum resistance is eventually near-universal in high-grade serous disease, and each new drug adds months, not years.","PARP inhibitor resistance (BRCA reversion, restored fork protection) has no approved counter; later-line PARP use has been curtailed by OS signals.","Immunotherapy fails in first-line disease; benefit is confined to PD-L1-positive platinum-resistant tumours.","Clear-cell, mucinous, and carcinosarcoma have no subtype-specific approved therapy.","FRα-low patients are excluded from mirvetuximab; next-generation ADCs are not yet approved.","Access to HRD testing, PARP inhibitors, and ADCs is limited outside high-income countries.","Optimal duration of maintenance and ctDNA-guided de-escalation are untested."],"prognosis":{"text":"In the United States, 52% of women diagnosed with ovarian cancer in 2016-2022 were alive five years later, relative to women of the same age without the disease. The problem is late diagnosis: 54% of cases are found after distant spread, with five-year relative survival of 31.5%, against 91.9% for the 22% found while confined to the ovary and 70.1% for regional disease (18% of cases). The figures cover the years PARP inhibitor maintenance was being adopted and only partly reflect it.","sources":[{"label":"SEER Cancer Stat Facts: Ovarian Cancer","url":"https://seer.cancer.gov/statfacts/html/ovary.html"}]}},"route":"/cancers/ovarian/","neighbours":{"pairing":[{"id":"caution-pd1-first-line-ovarian","kind":"pairing","name":"Caution: checkpoint inhibitors in first-line ovarian cancer","route":"/pairings/caution-pd1-first-line-ovarian/"},{"id":"hipec-at-interval-surgery","kind":"pairing","name":"HIPEC at interval cytoreductive surgery","route":"/pairings/hipec-at-interval-surgery/"},{"id":"parp-plus-bevacizumab","kind":"pairing","name":"PARP inhibitor + bevacizumab maintenance (HRD-positive)","route":"/pairings/parp-plus-bevacizumab/"},{"id":"platinum-plus-hrd","kind":"pairing","name":"Platinum chemotherapy in HRD tumours","route":"/pairings/platinum-plus-hrd/"}],"roadmap":[{"id":"adc-generations","kind":"roadmap","name":"ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs","route":"/roadmaps/adc-generations/"}],"collection":[{"id":"nhs-jewish-brca-testing","kind":"collection","name":"NHS Jewish BRCA Testing Programme","route":"/collections/nhs-jewish-brca-testing/"},{"id":"ovarian-cancer-research-alliance","kind":"collection","name":"Ovarian Cancer Research Alliance (OCRA)","route":"/collections/ovarian-cancer-research-alliance/"},{"id":"sharsheret","kind":"collection","name":"Sharsheret","route":"/collections/sharsheret/"}],"cancer":[{"id":"granulosa-cell-tumour","kind":"cancer","name":"Adult granulosa cell tumour of the ovary","route":"/cancers/granulosa-cell-tumour/"},{"id":"clear-cell-ovarian-cancer","kind":"cancer","name":"Clear cell ovarian cancer","route":"/cancers/clear-cell-ovarian-cancer/"},{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/"},{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/"},{"id":"low-grade-serous-ovarian-cancer","kind":"cancer","name":"Low-grade serous ovarian cancer","route":"/cancers/low-grade-serous-ovarian-cancer/"},{"id":"mucinous-ovarian-cancer","kind":"cancer","name":"Mucinous ovarian cancer","route":"/cancers/mucinous-ovarian-cancer/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"},{"id":"platinum-sensitive-ovarian-cancer","kind":"cancer","name":"Platinum-sensitive ovarian cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/"}],"idea":[{"id":"idea-tr2-hrd-functional-standard","kind":"idea","name":"A functional test for homologous recombination deficiency validated across laboratories","route":"/ideas/idea-tr2-hrd-functional-standard/"},{"id":"idea-bio1-adaptive-therapy-platform","kind":"idea","name":"A multi-cancer platform trial of adaptive (dose-holiday) therapy","route":"/ideas/idea-bio1-adaptive-therapy-platform/"},{"id":"idea-tr2-perpetual-platforms","kind":"idea","name":"A perpetual platform trial in every major cancer, funded as infrastructure","route":"/ideas/idea-tr2-perpetual-platforms/"},{"id":"idea-prev-reflex-germline-testing","kind":"idea","name":"Automatic germline testing for every cancer type where it changes care","route":"/ideas/idea-prev-reflex-germline-testing/"},{"id":"idea-ctdna-guided-parp-duration","kind":"idea","name":"ctDNA-guided duration of PARP maintenance","route":"/ideas/idea-ctdna-guided-parp-duration/"},{"id":"idea-tr1-adaptive-therapy-randomised-phase-2","kind":"idea","name":"Evolution-guided 'adaptive therapy' dosing tested in randomised phase 2 trials","route":"/ideas/idea-tr1-adaptive-therapy-randomised-phase-2/"},{"id":"idea-mced-plus-fapi","kind":"idea","name":"FAPI PET as the workup for MCED positives","route":"/ideas/idea-mced-plus-fapi/"},{"id":"idea-prev-traceback-deceased-probands","kind":"idea","name":"Go back to families of women who died of ovarian cancer and offer BRCA testing","route":"/ideas/idea-prev-traceback-deceased-probands/"},{"id":"idea-bio2-mechanism-defined-baskets","kind":"idea","name":"Group trials by broken mechanism, not by organ or single mutation","route":"/ideas/idea-bio2-mechanism-defined-baskets/"},{"id":"idea-targeting-aneuploidy","kind":"idea","name":"Is aneuploidy itself a druggable vulnerability?","route":"/ideas/idea-targeting-aneuploidy/"},{"id":"idea-moon-cold-to-hot-programme","kind":"idea","name":"Make every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours","route":"/ideas/idea-moon-cold-to-hot-programme/"},{"id":"idea-acc-mainstream-tele-genetic-counselling","kind":"idea","name":"Oncology teams order germline tests; tele-genetic counsellors handle the results","route":"/ideas/idea-acc-mainstream-tele-genetic-counselling/"},{"id":"idea-senolytics-after-chemo","kind":"idea","name":"One-two punch: clear senescent cells after chemotherapy","route":"/ideas/idea-senolytics-after-chemo/"},{"id":"idea-moon-population-germline-screening","kind":"idea","name":"Population germline screening for hereditary cancer genes with cascade testing","route":"/ideas/idea-moon-population-germline-screening/"},{"id":"idea-prev-opportunistic-salpingectomy-default","kind":"idea","name":"Remove the fallopian tubes during any pelvic surgery once childbearing is finished","route":"/ideas/idea-prev-opportunistic-salpingectomy-default/"},{"id":"idea-fra-adc-sequencing-ovarian","kind":"idea","name":"Sequence folate-receptor ADCs by payload class","route":"/ideas/idea-fra-adc-sequencing-ovarian/"},{"id":"idea-bio2-intracavitary-immunotherapy","kind":"idea","name":"Treat the body cavity, not the bloodstream, for surface spread","route":"/ideas/idea-bio2-intracavitary-immunotherapy/"},{"id":"idea-bio1-cin-vulnerability-kif18a","kind":"idea","name":"Turn chromosomal chaos into a weakness with KIF18A inhibitors","route":"/ideas/idea-bio1-cin-vulnerability-kif18a/"},{"id":"idea-chip-risk-modifiers","kind":"idea","name":"Which patients' blood clones will become leukaemia after treatment?","route":"/ideas/idea-chip-risk-modifiers/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"rejuv-measure-epro-as-treatment","kind":"technology","name":"Asking people how they are, every week, as a treatment in its own right","route":"/technologies/rejuv-measure-epro-as-treatment/"},{"id":"astatine-211-alpha-therapy","kind":"technology","name":"Astatine-211 alpha therapy","route":"/technologies/astatine-211-alpha-therapy/"},{"id":"atr-chk1-inhibitors","kind":"technology","name":"ATR and CHK1 inhibitors","route":"/technologies/atr-chk1-inhibitors/"},{"id":"nerve-tumour-denervation","kind":"technology","name":"Cancer neuroscience: cutting the nerve supply","route":"/technologies/nerve-tumour-denervation/"},{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/"},{"id":"enteral-parenteral-nutrition","kind":"technology","name":"Enteral and parenteral nutrition support","route":"/technologies/enteral-parenteral-nutrition/"},{"id":"sterile-injectable-generics-manufacturing","kind":"technology","name":"Generic sterile injectables (the 2023 platinum shortage)","route":"/technologies/sterile-injectable-generics-manufacturing/"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/"},{"id":"hand-held-ultrasound","kind":"technology","name":"Hand-held and point-of-care ultrasound","route":"/technologies/hand-held-ultrasound/"},{"id":"hearing-after-platinum-chemotherapy","kind":"technology","name":"Hearing and tinnitus after platinum chemotherapy","route":"/technologies/hearing-after-platinum-chemotherapy/"},{"id":"high-dose-vitamin-c","kind":"technology","name":"High-dose intravenous vitamin C","route":"/technologies/high-dose-vitamin-c/"},{"id":"hipec","kind":"technology","name":"HIPEC / PIPAC (intraperitoneal chemotherapy)","route":"/technologies/hipec/"},{"id":"hipec-pipac-devices","kind":"technology","name":"HIPEC perfusion pumps and PIPAC nebulisers","route":"/technologies/hipec-pipac-devices/"},{"id":"hrd-testing","kind":"technology","name":"HRD & BRCA testing","route":"/technologies/hrd-testing/"},{"id":"hrd-genomic-scar-scores","kind":"technology","name":"HRD genomic scar scores (GIS, LOH, HRDetect)","route":"/technologies/hrd-genomic-scar-scores/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"intraoperative-fluorescence-imaging-systems","kind":"technology","name":"Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath)","route":"/technologies/intraoperative-fluorescence-imaging-systems/"},{"id":"menopause-after-cancer-treatment","kind":"technology","name":"Menopause brought on by cancer treatment, and the options for it","route":"/technologies/menopause-after-cancer-treatment/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"},{"id":"nail-changes-after-chemotherapy","kind":"technology","name":"Nails after chemotherapy: lifting, ridges and discolouration","route":"/technologies/nail-changes-after-chemotherapy/"},{"id":"cipn-recovery-and-treatment","kind":"technology","name":"Nerve damage from chemotherapy: what recovers, and what helps","route":"/technologies/cipn-recovery-and-treatment/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"parp-pet","kind":"technology","name":"PARP PET","route":"/technologies/parp-pet/"},{"id":"parsortix-ctc-harvest","kind":"technology","name":"Parsortix label-free circulating tumour cell harvest","route":"/technologies/parsortix-ctc-harvest/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"rejuv-measure-pro-ctcae","kind":"technology","name":"PRO-CTCAE: side effects graded by the person having them","route":"/technologies/rejuv-measure-pro-ctcae/"},{"id":"rad51-foci-assay","kind":"technology","name":"RAD51 foci assay (functional HRD test)","route":"/technologies/rad51-foci-assay/"},{"id":"risk-reducing-salpingectomy","kind":"technology","name":"Risk-reducing and opportunistic salpingectomy","route":"/technologies/risk-reducing-salpingectomy/"},{"id":"robotic-surgery","kind":"technology","name":"Robotic & minimally invasive surgery","route":"/technologies/robotic-surgery/"},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/"},{"id":"serum-tumour-markers","kind":"technology","name":"Serum tumour markers: proper use and misuse","route":"/technologies/serum-tumour-markers/"},{"id":"rejuv-mind-sleep-after-cancer","kind":"technology","name":"Sleep after cancer: how common insomnia is, how long it lasts, and the treatment that works","route":"/technologies/rejuv-mind-sleep-after-cancer/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"},{"id":"ultrasound","kind":"technology","name":"Ultrasound","route":"/technologies/ultrasound/"},{"id":"vaginal-oestrogen-after-breast-cancer","kind":"technology","name":"Vaginal oestrogen after breast cancer: what the evidence says, and where it disagrees","route":"/technologies/vaginal-oestrogen-after-breast-cancer/"}],"target":[{"id":"abcb1","kind":"target","name":"ABCB1","route":"/targets/abcb1/"},{"id":"abcg2","kind":"target","name":"ABCG2","route":"/targets/abcg2/"},{"id":"ackr3","kind":"target","name":"ACKR3","route":"/targets/ackr3/"},{"id":"actl6a","kind":"target","name":"ACTL6A","route":"/targets/actl6a/"},{"id":"arhgap35","kind":"target","name":"ARHGAP35","route":"/targets/arhgap35/"},{"id":"arid2","kind":"target","name":"ARID2","route":"/targets/arid2/"},{"id":"asns","kind":"target","name":"ASNS","route":"/targets/asns/"},{"id":"ass1","kind":"target","name":"ASS1","route":"/targets/ass1/"},{"id":"atm","kind":"target","name":"ATM","route":"/targets/atm/"},{"id":"atp7b","kind":"target","name":"ATP7B","route":"/targets/atp7b/"},{"id":"atr","kind":"target","name":"ATR","route":"/targets/atr/"},{"id":"atrx","kind":"target","name":"ATRX","route":"/targets/atrx/"},{"id":"aurka","kind":"target","name":"AURKA","route":"/targets/aurka/"},{"id":"b7h4","kind":"target","name":"B7-H4 (VTCN1)","route":"/targets/b7h4/"},{"id":"bard1","kind":"target","name":"BARD1","route":"/targets/bard1/"},{"id":"blm","kind":"target","name":"BLM","route":"/targets/blm/"},{"id":"bmpr1a","kind":"target","name":"BMPR1A","route":"/targets/bmpr1a/"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"brip1","kind":"target","name":"BRIP1","route":"/targets/brip1/"},{"id":"bub1b","kind":"target","name":"BUB1B","route":"/targets/bub1b/"},{"id":"c11orf65","kind":"target","name":"C11orf65","route":"/targets/c11orf65/"},{"id":"card11","kind":"target","name":"CARD11","route":"/targets/card11/"},{"id":"cbl","kind":"target","name":"CBL","route":"/targets/cbl/"},{"id":"ccnd1","kind":"target","name":"CCND1","route":"/targets/ccnd1/"},{"id":"ccne1","kind":"target","name":"CCNE1","route":"/targets/ccne1/"},{"id":"cd44","kind":"target","name":"CD44","route":"/targets/cd44/"},{"id":"cdh1","kind":"target","name":"CDH1","route":"/targets/cdh1/"},{"id":"cdh6","kind":"target","name":"CDH6","route":"/targets/cdh6/"},{"id":"cdk12","kind":"target","name":"CDK12","route":"/targets/cdk12/"},{"id":"cdkn2a","kind":"target","name":"CDKN2A","route":"/targets/cdkn2a/"},{"id":"chek2","kind":"target","name":"CHEK2","route":"/targets/chek2/"},{"id":"cldn6","kind":"target","name":"Claudin 6","route":"/targets/cldn6/"},{"id":"ctnnb1","kind":"target","name":"CTNNB1","route":"/targets/ctnnb1/"},{"id":"ctnnd2","kind":"target","name":"CTNND2","route":"/targets/ctnnd2/"},{"id":"dicer1","kind":"target","name":"DICER1","route":"/targets/dicer1/"},{"id":"drosha","kind":"target","name":"DROSHA","route":"/targets/drosha/"},{"id":"ell","kind":"target","name":"ELL","route":"/targets/ell/"},{"id":"emsy","kind":"target","name":"EMSY","route":"/targets/emsy/"},{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/"},{"id":"epha2","kind":"target","name":"EphA2 receptor","route":"/targets/epha2/"},{"id":"ercc1","kind":"target","name":"ERCC1","route":"/targets/ercc1/"},{"id":"ercc2","kind":"target","name":"ERCC2","route":"/targets/ercc2/"},{"id":"ercc3","kind":"target","name":"ERCC3","route":"/targets/ercc3/"},{"id":"ercc5","kind":"target","name":"ERCC5","route":"/targets/ercc5/"},{"id":"ext1","kind":"target","name":"EXT1","route":"/targets/ext1/"},{"id":"ext2","kind":"target","name":"EXT2","route":"/targets/ext2/"},{"id":"fak","kind":"target","name":"FAK (PTK2)","route":"/targets/fak/"},{"id":"fanca","kind":"target","name":"FANCA","route":"/targets/fanca/"},{"id":"fancc","kind":"target","name":"FANCC","route":"/targets/fancc/"},{"id":"fancd2","kind":"target","name":"FANCD2","route":"/targets/fancd2/"},{"id":"fancm","kind":"target","name":"FANCM","route":"/targets/fancm/"},{"id":"fbxo11","kind":"target","name":"FBXO11","route":"/targets/fbxo11/"},{"id":"fgf19","kind":"target","name":"FGF19","route":"/targets/fgf19/"},{"id":"fgfr4","kind":"target","name":"FGFR4","route":"/targets/fgfr4/"},{"id":"fhit","kind":"target","name":"FHIT","route":"/targets/fhit/"},{"id":"fntb","kind":"target","name":"FNTB","route":"/targets/fntb/"},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"},{"id":"foxl2","kind":"target","name":"FOXL2","route":"/targets/foxl2/"},{"id":"foxo1","kind":"target","name":"FOXO1","route":"/targets/foxo1/"},{"id":"foxp1","kind":"target","name":"FOXP1","route":"/targets/foxp1/"},{"id":"gadd45a","kind":"target","name":"GADD45A","route":"/targets/gadd45a/"},{"id":"gpc5","kind":"target","name":"GPC5","route":"/targets/gpc5/"},{"id":"gstp1","kind":"target","name":"GSTP1","route":"/targets/gstp1/"},{"id":"hgf","kind":"target","name":"HGF","route":"/targets/hgf/"},{"id":"hnf1a","kind":"target","name":"HNF1A","route":"/targets/hnf1a/"},{"id":"hnf1b","kind":"target","name":"HNF1B","route":"/targets/hnf1b/"},{"id":"igf2","kind":"target","name":"IGF2","route":"/targets/igf2/"},{"id":"kat6a","kind":"target","name":"KAT6A","route":"/targets/kat6a/"},{"id":"kdm5c","kind":"target","name":"KDM5C","route":"/targets/kdm5c/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"},{"id":"lats1","kind":"target","name":"LATS1","route":"/targets/lats1/"},{"id":"lck","kind":"target","name":"LCK","route":"/targets/lck/"},{"id":"lilrb2","kind":"target","name":"LILRB2 (ILT4)","route":"/targets/lilrb2/"},{"id":"map3k1","kind":"target","name":"MAP3K1","route":"/targets/map3k1/"},{"id":"mecom","kind":"target","name":"MECOM","route":"/targets/mecom/"},{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/"},{"id":"mitf","kind":"target","name":"MITF","route":"/targets/mitf/"},{"id":"mlh1","kind":"target","name":"MLH1","route":"/targets/mlh1/"},{"id":"mllt10","kind":"target","name":"MLLT10","route":"/targets/mllt10/"},{"id":"mre11","kind":"target","name":"MRE11","route":"/targets/mre11/"},{"id":"msh2","kind":"target","name":"MSH2","route":"/targets/msh2/"},{"id":"msh6","kind":"target","name":"MSH6","route":"/targets/msh6/"},{"id":"muc16","kind":"target","name":"MUC16 (CA-125)","route":"/targets/muc16/"},{"id":"mus81","kind":"target","name":"MUS81","route":"/targets/mus81/"},{"id":"mutyh","kind":"target","name":"MUTYH","route":"/targets/mutyh/"},{"id":"myh9","kind":"target","name":"MYH9","route":"/targets/myh9/"},{"id":"nbea","kind":"target","name":"NBEA","route":"/targets/nbea/"},{"id":"nbn","kind":"target","name":"NBN","route":"/targets/nbn/"},{"id":"nf2","kind":"target","name":"NF2","route":"/targets/nf2/"},{"id":"nrg1","kind":"target","name":"NRG1","route":"/targets/nrg1/"},{"id":"nutm1","kind":"target","name":"NUTM1","route":"/targets/nutm1/"},{"id":"palb2","kind":"target","name":"PALB2","route":"/targets/palb2/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"},{"id":"parp2","kind":"target","name":"PARP2","route":"/targets/parp2/"},{"id":"parp3","kind":"target","name":"PARP3","route":"/targets/parp3/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"},{"id":"pik3cb","kind":"target","name":"PIK3CB","route":"/targets/pik3cb/"},{"id":"pik3r1","kind":"target","name":"PIK3R1","route":"/targets/pik3r1/"},{"id":"pms2","kind":"target","name":"PMS2","route":"/targets/pms2/"},{"id":"pola2","kind":"target","name":"POLA2","route":"/targets/pola2/"},{"id":"pold1","kind":"target","name":"POLD1","route":"/targets/pold1/"},{"id":"pold2","kind":"target","name":"POLD2","route":"/targets/pold2/"},{"id":"pold3","kind":"target","name":"POLD3","route":"/targets/pold3/"},{"id":"pold4","kind":"target","name":"POLD4","route":"/targets/pold4/"},{"id":"pole","kind":"target","name":"POLE","route":"/targets/pole/"},{"id":"pole2","kind":"target","name":"POLE2","route":"/targets/pole2/"},{"id":"pole3","kind":"target","name":"POLE3","route":"/targets/pole3/"},{"id":"polq","kind":"target","name":"POLQ","route":"/targets/polq/"},{"id":"ppm1d","kind":"target","name":"PPM1D","route":"/targets/ppm1d/"},{"id":"ppp2r1a","kind":"target","name":"PPP2R1A","route":"/targets/ppp2r1a/"},{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/"},{"id":"prdm1","kind":"target","name":"PRDM1","route":"/targets/prdm1/"},{"id":"prex2","kind":"target","name":"PREX2","route":"/targets/prex2/"},{"id":"prim1","kind":"target","name":"PRIM1","route":"/targets/prim1/"},{"id":"prim2","kind":"target","name":"PRIM2","route":"/targets/prim2/"},{"id":"prkn","kind":"target","name":"PRKN","route":"/targets/prkn/"},{"id":"ptprb","kind":"target","name":"PTPRB","route":"/targets/ptprb/"},{"id":"ptprd","kind":"target","name":"PTPRD","route":"/targets/ptprd/"},{"id":"ptprt","kind":"target","name":"PTPRT","route":"/targets/ptprt/"},{"id":"pvrig","kind":"target","name":"PVRIG (CD112R)","route":"/targets/pvrig/"},{"id":"rad50","kind":"target","name":"RAD50","route":"/targets/rad50/"},{"id":"rad51b","kind":"target","name":"RAD51B","route":"/targets/rad51b/"},{"id":"rad51c","kind":"target","name":"RAD51C","route":"/targets/rad51c/"},{"id":"rad51d","kind":"target","name":"RAD51D","route":"/targets/rad51d/"},{"id":"recql4","kind":"target","name":"RECQL4","route":"/targets/recql4/"},{"id":"rel","kind":"target","name":"REL","route":"/targets/rel/"},{"id":"rnf43","kind":"target","name":"RNF43","route":"/targets/rnf43/"},{"id":"rras2","kind":"target","name":"RRAS2","route":"/targets/rras2/"},{"id":"rrm2","kind":"target","name":"RRM2","route":"/targets/rrm2/"},{"id":"rrm2b","kind":"target","name":"RRM2B","route":"/targets/rrm2b/"},{"id":"runx1","kind":"target","name":"RUNX1","route":"/targets/runx1/"},{"id":"sdha","kind":"target","name":"SDHA","route":"/targets/sdha/"},{"id":"sdhaf2","kind":"target","name":"SDHAF2","route":"/targets/sdhaf2/"},{"id":"setd1b","kind":"target","name":"SETD1B","route":"/targets/setd1b/"},{"id":"smarca4","kind":"target","name":"SMARCA4","route":"/targets/smarca4/"},{"id":"smarcb1","kind":"target","name":"SMARCB1","route":"/targets/smarcb1/"},{"id":"spop","kind":"target","name":"SPOP","route":"/targets/spop/"},{"id":"stat1","kind":"target","name":"STAT1","route":"/targets/stat1/"},{"id":"stat3","kind":"target","name":"STAT3","route":"/targets/stat3/"},{"id":"stk11","kind":"target","name":"STK11","route":"/targets/stk11/"},{"id":"syk","kind":"target","name":"SYK","route":"/targets/syk/"},{"id":"tert","kind":"target","name":"TERT","route":"/targets/tert/"},{"id":"tet1","kind":"target","name":"TET1","route":"/targets/tet1/"},{"id":"txnrd1","kind":"target","name":"Thioredoxin reductase 1","route":"/targets/txnrd1/"},{"id":"tnc","kind":"target","name":"TNC","route":"/targets/tnc/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"},{"id":"trim24","kind":"target","name":"TRIM24","route":"/targets/trim24/"},{"id":"tubulin","kind":"target","name":"Tubulin (microtubules)","route":"/targets/tubulin/"},{"id":"ubr5","kind":"target","name":"UBR5","route":"/targets/ubr5/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"},{"id":"vps37a","kind":"target","name":"VPS37A","route":"/targets/vps37a/"},{"id":"wee1","kind":"target","name":"WEE1","route":"/targets/wee1/"},{"id":"wwtr1","kind":"target","name":"WWTR1","route":"/targets/wwtr1/"},{"id":"znf217","kind":"target","name":"ZNF217","route":"/targets/znf217/"},{"id":"znf521","kind":"target","name":"ZNF521","route":"/targets/znf521/"}],"drug":[{"id":"altretamine","kind":"drug","name":"Altretamine","route":"/drugs/altretamine/"},{"id":"amifostine","kind":"drug","name":"Amifostine","route":"/drugs/amifostine/"},{"id":"anetumab-ravtansine","kind":"drug","name":"Anetumab ravtansine","route":"/drugs/anetumab-ravtansine/"},{"id":"avutometinib-defactinib","kind":"drug","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/"},{"id":"avzo-021","kind":"drug","name":"AVZO-021","route":"/drugs/avzo-021/"},{"id":"azd5335","kind":"drug","name":"AZD5335","route":"/drugs/azd5335/"},{"id":"azd8421","kind":"drug","name":"AZD8421","route":"/drugs/azd8421/"},{"id":"azenosertib","kind":"drug","name":"Azenosertib","route":"/drugs/azenosertib/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"bracanalysis-cdx","kind":"drug","name":"BRACAnalysis CDx","route":"/drugs/bracanalysis-cdx/"},{"id":"brenetafusp","kind":"drug","name":"Brenetafusp","route":"/drugs/brenetafusp/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"catumaxomab","kind":"drug","name":"Catumaxomab","route":"/drugs/catumaxomab/"},{"id":"chiauranib","kind":"drug","name":"Chiauranib","route":"/drugs/chiauranib/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"cyh33","kind":"drug","name":"CYH33","route":"/drugs/cyh33/"},{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"gotistobart","kind":"drug","name":"Gotistobart","route":"/drugs/gotistobart/"},{"id":"hlx43","kind":"drug","name":"HLX43","route":"/drugs/hlx43/"},{"id":"hs-20089","kind":"drug","name":"HS-20089","route":"/drugs/hs-20089/"},{"id":"ibi354","kind":"drug","name":"IBI354","route":"/drugs/ibi354/"},{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/"},{"id":"incb123667","kind":"drug","name":"INCB123667","route":"/drugs/incb123667/"},{"id":"ipatasertib","kind":"drug","name":"Ipatasertib","route":"/drugs/ipatasertib/"},{"id":"jk08","kind":"drug","name":"JK08","route":"/drugs/jk08/"},{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/"},{"id":"lorigerlimab","kind":"drug","name":"Lorigerlimab","route":"/drugs/lorigerlimab/"},{"id":"luveltamab-tazevibulin","kind":"drug","name":"Luveltamab tazevibulin","route":"/drugs/luveltamab-tazevibulin/"},{"id":"m701","kind":"drug","name":"M701","route":"/drugs/m701/"},{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/"},{"id":"mychoice-cdx","kind":"drug","name":"myChoice CDx","route":"/drugs/mychoice-cdx/"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"},{"id":"nuv-1511","kind":"drug","name":"NUV-1511","route":"/drugs/nuv-1511/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"olvimulogene-nanivacirepvec","kind":"drug","name":"Olvimulogene nanivacirepvec","route":"/drugs/olvimulogene-nanivacirepvec/"},{"id":"oregovomab","kind":"drug","name":"Oregovomab","route":"/drugs/oregovomab/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pafolacianine","kind":"drug","name":"Pafolacianine","route":"/drugs/pafolacianine/"},{"id":"palacaparib","kind":"drug","name":"Palacaparib","route":"/drugs/palacaparib/"},{"id":"pamiparib","kind":"drug","name":"Pamiparib","route":"/drugs/pamiparib/"},{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pf-08634404","kind":"drug","name":"PF-08634404","route":"/drugs/pf-08634404/"},{"id":"puxitatug-samrotecan","kind":"drug","name":"Puxitatug samrotecan","route":"/drugs/puxitatug-samrotecan/"},{"id":"raludotatug-deruxtecan","kind":"drug","name":"Raludotatug deruxtecan","route":"/drugs/raludotatug-deruxtecan/"},{"id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/"},{"id":"rinatabart-sesutecan","kind":"drug","name":"Rinatabart sesutecan","route":"/drugs/rinatabart-sesutecan/"},{"id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/"},{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"},{"id":"imp4927","kind":"drug","name":"Senaparib (IMP4297)","route":"/drugs/imp4927/"},{"id":"shr-a1921","kind":"drug","name":"SHR-A1921","route":"/drugs/shr-a1921/"},{"id":"sofetabart-mipitecan","kind":"drug","name":"Sofetabart Mipitecan","route":"/drugs/sofetabart-mipitecan/"},{"id":"talc-sclerosant","kind":"drug","name":"Talc (intrapleural)","route":"/drugs/talc-sclerosant/"},{"id":"theo-260","kind":"drug","name":"THEO-260","route":"/drugs/theo-260/"},{"id":"thiotepa","kind":"drug","name":"Thiotepa","route":"/drugs/thiotepa/"},{"id":"tilt-123","kind":"drug","name":"TILT-123","route":"/drugs/tilt-123/"},{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/"},{"id":"trabectedin","kind":"drug","name":"Trabectedin","route":"/drugs/trabectedin/"},{"id":"ubamatamab","kind":"drug","name":"Ubamatamab","route":"/drugs/ubamatamab/"},{"id":"upifitamab-rilsodotin","kind":"drug","name":"Upifitamab rilsodotin","route":"/drugs/upifitamab-rilsodotin/"},{"id":"utomilumab","kind":"drug","name":"Utomilumab","route":"/drugs/utomilumab/"},{"id":"vb15010","kind":"drug","name":"VB15010","route":"/drugs/vb15010/"},{"id":"vudalimab","kind":"drug","name":"Vudalimab","route":"/drugs/vudalimab/"},{"id":"xnw27011","kind":"drug","name":"XNW27011","route":"/drugs/xnw27011/"}],"company":[{"id":"a2-biotherapeutics","kind":"company","name":"A2 Biotherapeutics","route":"/companies/a2-biotherapeutics/"},{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"},{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","route":"/companies/acrivon-therapeutics/"},{"id":"ago-study-group","kind":"company","name":"AGO Study Group","route":"/companies/ago-study-group/"},{"id":"angle-plc","kind":"company","name":"ANGLE plc","route":"/companies/angle-plc/"},{"id":"aoa-dx","kind":"company","name":"AOA Dx","route":"/companies/aoa-dx/"},{"id":"arcagy-gineco","kind":"company","name":"ARCAGY-GINECO","route":"/companies/arcagy-gineco/"},{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/"},{"id":"artios-pharma","kind":"company","name":"Artios Pharma","route":"/companies/artios-pharma/"},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"belmont-medical-technologies","kind":"company","name":"Belmont Medical Technologies","route":"/companies/belmont-medical-technologies/"},{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/"},{"id":"capnomed","kind":"company","name":"Capnomed (Reger Medizintechnik)","route":"/companies/capnomed/"},{"id":"clearnote-health","kind":"company","name":"ClearNote Health","route":"/companies/clearnote-health/"},{"id":"clovis-oncology","kind":"company","name":"Clovis Oncology","route":"/companies/clovis-oncology/"},{"id":"compugen","kind":"company","name":"Compugen","route":"/companies/compugen/"},{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/"},{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"},{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/"},{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","route":"/companies/evopoint-biosciences/"},{"id":"fujirebio","kind":"company","name":"Fujirebio","route":"/companies/fujirebio/"},{"id":"genelux","kind":"company","name":"Genelux","route":"/companies/genelux/"},{"id":"generate-biomedicines","kind":"company","name":"Generate:Biomedicines","route":"/companies/generate-biomedicines/"},{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/"},{"id":"gi-innovation","kind":"company","name":"GI Innovation","route":"/companies/gi-innovation/"},{"id":"gog-foundation","kind":"company","name":"GOG Foundation","route":"/companies/gog-foundation/"},{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"},{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","route":"/companies/haihe-biopharma/"},{"id":"immunovaccine","kind":"company","name":"Immunovaccine (IMV)","route":"/companies/immunovaccine/"},{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/"},{"id":"imunon","kind":"company","name":"Imunon","route":"/companies/imunon/"},{"id":"intodna","kind":"company","name":"intoDNA","route":"/companies/intodna/"},{"id":"inxmed","kind":"company","name":"InxMed","route":"/companies/inxmed/"},{"id":"kiyatec","kind":"company","name":"Kiyatec","route":"/companies/kiyatec/"},{"id":"kymera","kind":"company","name":"Kymera Therapeutics","route":"/companies/kymera/"},{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"},{"id":"mersana","kind":"company","name":"Mersana Therapeutics","route":"/companies/mersana/"},{"id":"monte-rosa","kind":"company","name":"Monte Rosa Therapeutics","route":"/companies/monte-rosa/"},{"id":"mrc-ctu","kind":"company","name":"MRC Clinical Trials Unit at UCL","route":"/companies/mrc-ctu/"},{"id":"myriad-genetics","kind":"company","name":"Myriad Genetics","route":"/companies/myriad-genetics/"},{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"},{"id":"nuvation-bio","kind":"company","name":"Nuvation Bio","route":"/companies/nuvation-bio/"},{"id":"on-target-laboratories","kind":"company","name":"On Target Laboratories","route":"/companies/on-target-laboratories/"},{"id":"oncoc4","kind":"company","name":"OncoC4","route":"/companies/oncoc4/"},{"id":"ose-immunotherapeutics","kind":"company","name":"OSE Immunotherapeutics","route":"/companies/ose-immunotherapeutics/"},{"id":"outcomes4me","kind":"company","name":"Outcomes4Me","route":"/companies/outcomes4me/"},{"id":"pharmaand","kind":"company","name":"pharma&","route":"/companies/pharmaand/"},{"id":"profoundbio","kind":"company","name":"ProfoundBio","route":"/companies/profoundbio/"},{"id":"radiopharm-theranostics","kind":"company","name":"Radiopharm Theranostics","route":"/companies/radiopharm-theranostics/"},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"},{"id":"scancell","kind":"company","name":"Scancell","route":"/companies/scancell/"},{"id":"shenzhen-ionova-life-sciences","kind":"company","name":"Shenzhen Ionova Life Sciences","route":"/companies/shenzhen-ionova-life-sciences/"},{"id":"sutro-biopharma","kind":"company","name":"Sutro Biopharma","route":"/companies/sutro-biopharma/"},{"id":"telik","kind":"company","name":"Telik","route":"/companies/telik/"},{"id":"torl-biotherapeutics","kind":"company","name":"TORL BioTherapeutics","route":"/companies/torl-biotherapeutics/"},{"id":"tradewind-bioscience","kind":"company","name":"Tradewind BioScience","route":"/companies/tradewind-bioscience/"},{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","route":"/companies/tubulis/"},{"id":"verastem","kind":"company","name":"Verastem Oncology","route":"/companies/verastem/"},{"id":"xencor","kind":"company","name":"Xencor","route":"/companies/xencor/"},{"id":"zentalis-pharmaceuticals","kind":"company","name":"Zentalis Pharmaceuticals","route":"/companies/zentalis-pharmaceuticals/"}],"pathway":[{"id":"base-excision-repair-parp","kind":"pathway","name":"Base excision repair, PARP & alkylation damage","route":"/pathways/base-excision-repair-parp/"},{"id":"ddr","kind":"pathway","name":"DNA damage response & homologous recombination","route":"/pathways/ddr/"},{"id":"homologous-recombination-repair","kind":"pathway","name":"Double-strand break repair: HR versus end joining","route":"/pathways/homologous-recombination-repair/"},{"id":"lipid-metabolism-cancer","kind":"pathway","name":"Lipid synthesis, uptake & cholesterol","route":"/pathways/lipid-metabolism-cancer/"},{"id":"organ-tropism-seed-soil","kind":"pathway","name":"Organ tropism: seed and soil","route":"/pathways/organ-tropism-seed-soil/"},{"id":"p53-cell-cycle","kind":"pathway","name":"p53 / RB / cell-cycle checkpoint","route":"/pathways/p53-cell-cycle/"},{"id":"swi-snf-chromatin","kind":"pathway","name":"SWI/SNF chromatin remodelling","route":"/pathways/swi-snf-chromatin/"},{"id":"angiogenic-switch","kind":"pathway","name":"The angiogenic switch & tumour vessels","route":"/pathways/angiogenic-switch/"},{"id":"cell-cycle-engine-cdks","kind":"pathway","name":"The cell-cycle engine (cyclins & CDKs)","route":"/pathways/cell-cycle-engine-cdks/"},{"id":"p53-mdm2-axis","kind":"pathway","name":"The p53 network (guardian of the genome)","route":"/pathways/p53-mdm2-axis/"}],"term":[{"id":"rejuv-second-alkylating-agents-and-myeloid-neoplasms","kind":"term","name":"Alkylating agents and therapy-related myeloid neoplasms","route":"/terms/rejuv-second-alkylating-agents-and-myeloid-neoplasms/"},{"id":"ca-125","kind":"term","name":"CA-125","route":"/terms/ca-125/"},{"id":"cps","kind":"term","name":"Combined positive score (CPS)","route":"/terms/cps/"},{"id":"debulking","kind":"term","name":"Debulking (cytoreductive surgery)","route":"/terms/debulking/"},{"id":"founder-mutation","kind":"term","name":"Founder mutation (BRCA1 185delAG and 5382insC, BRCA2 6174delT)","route":"/terms/founder-mutation/"},{"id":"gbrca-mutation","kind":"term","name":"Germline BRCA mutation (gBRCA)","route":"/terms/gbrca-mutation/"},{"id":"hgsoc","kind":"term","name":"High-grade serous ovarian carcinoma (HGSOC)","route":"/terms/hgsoc/"},{"id":"hipec-procedure","kind":"term","name":"HIPEC (hyperthermic intraperitoneal chemotherapy)","route":"/terms/hipec-procedure/"},{"id":"intraperitoneal-chemotherapy","kind":"term","name":"Intraperitoneal (IP) chemotherapy","route":"/terms/intraperitoneal-chemotherapy/"},{"id":"lgsoc","kind":"term","name":"Low-grade serous ovarian cancer (LGSOC)","route":"/terms/lgsoc/"},{"id":"maintenance-therapy","kind":"term","name":"Maintenance therapy","route":"/terms/maintenance-therapy/"},{"id":"pleural-effusion","kind":"term","name":"Malignant pleural effusion and ascites","route":"/terms/pleural-effusion/"},{"id":"obesity-related-cancers","kind":"term","name":"Obesity-related cancers (IARC list of 13)","route":"/terms/obesity-related-cancers/"},{"id":"peritoneal-metastasis","kind":"term","name":"Peritoneal metastasis","route":"/terms/peritoneal-metastasis/"},{"id":"peritoneum","kind":"term","name":"Peritoneum and peritoneal metastases","route":"/terms/peritoneum/"},{"id":"rejuv-second-platinum-and-parp-inhibitors","kind":"term","name":"Platinum drugs and PARP inhibitors: the newer leukaemia risk","route":"/terms/rejuv-second-platinum-and-parp-inhibitors/"},{"id":"platinum-sensitivity","kind":"term","name":"Platinum-sensitive / platinum-resistant","route":"/terms/platinum-sensitivity/"},{"id":"risk-reducing-surgery-brca-carriers","kind":"term","name":"Risk-reducing surgery for BRCA carriers (bilateral and contralateral mastectomy, salpingo-oophorectomy)","route":"/terms/risk-reducing-surgery-brca-carriers/"},{"id":"salpingo-oophorectomy","kind":"term","name":"Salpingo-oophorectomy","route":"/terms/salpingo-oophorectomy/"},{"id":"synthetic-lethality","kind":"term","name":"Synthetic lethality","route":"/terms/synthetic-lethality/"},{"id":"tp53-mutated","kind":"term","name":"TP53-mutated (p53-abnormal)","route":"/terms/tp53-mutated/"},{"id":"tumour-marker","kind":"term","name":"Tumour marker","route":"/terms/tumour-marker/"}],"trial":[{"id":"nct07432633","kind":"trial","name":"[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07432633/"},{"id":"nct07702292","kind":"trial","name":"[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07702292/"},{"id":"nct07189871","kind":"trial","name":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","route":"/trials/nct07189871/"},{"id":"nct05335993","kind":"trial","name":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","route":"/trials/nct05335993/"},{"id":"nct06843447","kind":"trial","name":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","route":"/trials/nct06843447/"},{"id":"nct06840002","kind":"trial","name":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","route":"/trials/nct06840002/"},{"id":"nct07714668","kind":"trial","name":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","route":"/trials/nct07714668/"},{"id":"nct07318558","kind":"trial","name":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","route":"/trials/nct07318558/"},{"id":"nct06888921","kind":"trial","name":"A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer","route":"/trials/nct06888921/"},{"id":"nct03602859","kind":"trial","name":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","route":"/trials/nct03602859/"},{"id":"nct06188520","kind":"trial","name":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ","route":"/trials/nct06188520/"},{"id":"nct04686682","kind":"trial","name":"A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","route":"/trials/nct04686682/"},{"id":"nct04641247","kind":"trial","name":"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study","route":"/trials/nct04641247/"},{"id":"nct07109726","kind":"trial","name":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","route":"/trials/nct07109726/"},{"id":"nct05199272","kind":"trial","name":"A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies","route":"/trials/nct05199272/"},{"id":"nct06710288","kind":"trial","name":"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P","route":"/trials/nct06710288/"},{"id":"nct02734004","kind":"trial","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","route":"/trials/nct02734004/"},{"id":"nct05902988","kind":"trial","name":"A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer","route":"/trials/nct05902988/"},{"id":"nct05123482","kind":"trial","name":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","route":"/trials/nct05123482/"},{"id":"nct06769152","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors","route":"/trials/nct06769152/"},{"id":"nct06994195","kind":"trial","name":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANK","route":"/trials/nct06994195/"},{"id":"nct04931342","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","route":"/trials/nct04931342/"},{"id":"nct04657068","kind":"trial","name":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors","route":"/trials/nct04657068/"},{"id":"nct06072781","kind":"trial","name":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","route":"/trials/nct06072781/"},{"id":"nct06682572","kind":"trial","name":"A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients","route":"/trials/nct06682572/"},{"id":"nct05128825","kind":"trial","name":"A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer","route":"/trials/nct05128825/"},{"id":"nct07546500","kind":"trial","name":"A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","route":"/trials/nct07546500/"},{"id":"nct06434610","kind":"trial","name":"A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.","route":"/trials/nct06434610/"},{"id":"nct06873555","kind":"trial","name":"A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors","route":"/trials/nct06873555/"},{"id":"nct06003231","kind":"trial","name":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","route":"/trials/nct06003231/"},{"id":"nct06751329","kind":"trial","name":"A Study of DM002 in Patients With Advanced Solid Tumors","route":"/trials/nct06751329/"},{"id":"nct05377996","kind":"trial","name":"A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors","route":"/trials/nct05377996/"},{"id":"nct04169997","kind":"trial","name":"A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer","route":"/trials/nct04169997/"},{"id":"nct07023627","kind":"trial","name":"A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","route":"/trials/nct07023627/"},{"id":"nct07042802","kind":"trial","name":"A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer","route":"/trials/nct07042802/"},{"id":"nct06730347","kind":"trial","name":"A Study of Lorigerlimab in Participants With Advanced Solid Tumors","route":"/trials/nct06730347/"},{"id":"nct06365853","kind":"trial","name":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit","route":"/trials/nct06365853/"},{"id":"nct06395519","kind":"trial","name":"A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies","route":"/trials/nct06395519/"},{"id":"nct06504147","kind":"trial","name":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","route":"/trials/nct06504147/"},{"id":"nct06828354","kind":"trial","name":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","route":"/trials/nct06828354/"},{"id":"nct06390995","kind":"trial","name":"A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors","route":"/trials/nct06390995/"},{"id":"nct05032040","kind":"trial","name":"A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies","route":"/trials/nct05032040/"},{"id":"nct06682988","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primar","route":"/trials/nct06682988/"},{"id":"nct07059845","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult","route":"/trials/nct07059845/"},{"id":"nct06890338","kind":"trial","name":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo","route":"/trials/nct06890338/"},{"id":"nct07024784","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1","route":"/trials/nct07024784/"},{"id":"nct06522828","kind":"trial","name":"A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients","route":"/trials/nct06522828/"},{"id":"nct05043922","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma","route":"/trials/nct05043922/"},{"id":"nct06824467","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl","route":"/trials/nct06824467/"},{"id":"nct06051695","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","route":"/trials/nct06051695/"},{"id":"nct05824975","kind":"trial","name":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu","route":"/trials/nct05824975/"},{"id":"nct07612891","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor","route":"/trials/nct07612891/"},{"id":"nct07610798","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations","route":"/trials/nct07610798/"},{"id":"nct04590326","kind":"trial","name":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata","route":"/trials/nct04590326/"},{"id":"nct07286266","kind":"trial","name":"A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","route":"/trials/nct07286266/"},{"id":"nct05081609","kind":"trial","name":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other","route":"/trials/nct05081609/"},{"id":"nct07213804","kind":"trial","name":"A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer","route":"/trials/nct07213804/"},{"id":"nct04503265","kind":"trial","name":"A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies","route":"/trials/nct04503265/"},{"id":"nct00880360","kind":"trial","name":"A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer","route":"/trials/nct00880360/"},{"id":"nct02346747","kind":"trial","name":"A Trial of Vigil for Participants With Ovarian Cancer","route":"/trials/nct02346747/"},{"id":"nct05601752","kind":"trial","name":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","route":"/trials/nct05601752/"},{"id":"nct06560112","kind":"trial","name":"An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer","route":"/trials/nct06560112/"},{"id":"nct07604766","kind":"trial","name":"An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can","route":"/trials/nct07604766/"},{"id":"nct00532194","kind":"trial","name":"An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer","route":"/trials/nct00532194/"},{"id":"athena-mono","kind":"trial","name":"ATHENA-MONO / GOG-3020","route":"/trials/athena-mono/"},{"id":"aurelia","kind":"trial","name":"AURELIA","route":"/trials/aurelia/"},{"id":"nct07218809","kind":"trial","name":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","route":"/trials/nct07218809/"},{"id":"nct02568267","kind":"trial","name":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme","route":"/trials/nct02568267/"},{"id":"nct04752826","kind":"trial","name":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","route":"/trials/nct04752826/"},{"id":"nct03949283","kind":"trial","name":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","route":"/trials/nct03949283/"},{"id":"nct06690775","kind":"trial","name":"CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","route":"/trials/nct06690775/"},{"id":"nct07322094","kind":"trial","name":"CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov","route":"/trials/nct07322094/"},{"id":"nct07125391","kind":"trial","name":"Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer","route":"/trials/nct07125391/"},{"id":"nct04921527","kind":"trial","name":"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer","route":"/trials/nct04921527/"},{"id":"nct06686030","kind":"trial","name":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","route":"/trials/nct06686030/"},{"id":"nct05059522","kind":"trial","name":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing","route":"/trials/nct05059522/"},{"id":"nct04884360","kind":"trial","name":"D9319C00001- 1L OC Mono Global RCT","route":"/trials/nct04884360/"},{"id":"desktop-iii","kind":"trial","name":"DESKTOP III / ENGOT-ov20","route":"/trials/desktop-iii/"},{"id":"nct07589543","kind":"trial","name":"Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer","route":"/trials/nct07589543/"},{"id":"nct07480954","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","route":"/trials/nct07480954/"},{"id":"nct07617753","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2","route":"/trials/nct07617753/"},{"id":"duo-o","kind":"trial","name":"DUO-O / ENGOT-ov46","route":"/trials/duo-o/"},{"id":"nct06926075","kind":"trial","name":"Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","route":"/trials/nct06926075/"},{"id":"nct05281471","kind":"trial","name":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","route":"/trials/nct05281471/"},{"id":"nct06303505","kind":"trial","name":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC","route":"/trials/nct06303505/"},{"id":"nct03319628","kind":"trial","name":"First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b","route":"/trials/nct03319628/"},{"id":"nct05804370","kind":"trial","name":"Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)","route":"/trials/nct05804370/"},{"id":"gog-0218-icon7","kind":"trial","name":"GOG-0218 & ICON7 (bevacizumab)","route":"/trials/gog-0218-icon7/"},{"id":"nct06855069","kind":"trial","name":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","route":"/trials/nct06855069/"},{"id":"nct06014190","kind":"trial","name":"HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer","route":"/trials/nct06014190/"},{"id":"nct06014528","kind":"trial","name":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren","route":"/trials/nct06014528/"},{"id":"nct05551507","kind":"trial","name":"IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer","route":"/trials/nct05551507/"},{"id":"nct00004157","kind":"trial","name":"Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors","route":"/trials/nct00004157/"},{"id":"nct03878849","kind":"trial","name":"Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer","route":"/trials/nct03878849/"},{"id":"nct06787612","kind":"trial","name":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","route":"/trials/nct06787612/"},{"id":"keynote-b96","kind":"trial","name":"KEYNOTE-B96 / ENGOT-ov65","route":"/trials/keynote-b96/"},{"id":"nct06710756","kind":"trial","name":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","route":"/trials/nct06710756/"},{"id":"nct03519230","kind":"trial","name":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer","route":"/trials/nct03519230/"},{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","route":"/trials/mirasol/"},{"id":"nct04274426","kind":"trial","name":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","route":"/trials/nct04274426/"},{"id":"nct05456685","kind":"trial","name":"Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov","route":"/trials/nct05456685/"},{"id":"nct05445778","kind":"trial","name":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C","route":"/trials/nct05445778/"},{"id":"nct05329532","kind":"trial","name":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer","route":"/trials/nct05329532/"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/"},{"id":"nct01874353","kind":"trial","name":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","route":"/trials/nct01874353/"},{"id":"nct05446298","kind":"trial","name":"ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer","route":"/trials/nct05446298/"},{"id":"nct05271318","kind":"trial","name":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) ","route":"/trials/nct05271318/"},{"id":"nct05735080","kind":"trial","name":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer","route":"/trials/nct05735080/"},{"id":"nct04938583","kind":"trial","name":"Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer","route":"/trials/nct04938583/"},{"id":"nct04498117","kind":"trial","name":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","route":"/trials/nct04498117/"},{"id":"nct05605535","kind":"trial","name":"Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer","route":"/trials/nct05605535/"},{"id":"ovhipec-1","kind":"trial","name":"OVHIPEC-1","route":"/trials/ovhipec-1/"},{"id":"nct03268382","kind":"trial","name":"p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246","route":"/trials/nct03268382/"},{"id":"paola-1","kind":"trial","name":"PAOLA-1 / ENGOT-ov25","route":"/trials/paola-1/"},{"id":"nct04553133","kind":"trial","name":"PF-07104091 as a Single Agent and in Combination Therapy","route":"/trials/nct04553133/"},{"id":"nct03907852","kind":"trial","name":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","route":"/trials/nct03907852/"},{"id":"nct06915025","kind":"trial","name":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat","route":"/trials/nct06915025/"},{"id":"nct04152499","kind":"trial","name":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","route":"/trials/nct04152499/"},{"id":"nct06819215","kind":"trial","name":"Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct06819215/"},{"id":"nct05797168","kind":"trial","name":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","route":"/trials/nct05797168/"},{"id":"nct05739981","kind":"trial","name":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","route":"/trials/nct05739981/"},{"id":"nct00563836","kind":"trial","name":"Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer","route":"/trials/nct00563836/"},{"id":"prima","kind":"trial","name":"PRIMA / ENGOT-OV26","route":"/trials/prima/"},{"id":"rainfol-01","kind":"trial","name":"RAINFOL-01 (Rina-S)","route":"/trials/rainfol-01/"},{"id":"ramp-201","kind":"trial","name":"RAMP 201","route":"/trials/ramp-201/"},{"id":"nct00189345","kind":"trial","name":"Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients","route":"/trials/nct00189345/"},{"id":"nct05870748","kind":"trial","name":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","route":"/trials/nct05870748/"},{"id":"rejoice-ovarian01","kind":"trial","name":"REJOICE-Ovarian01","route":"/trials/rejoice-ovarian01/"},{"id":"nct06906341","kind":"trial","name":"Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers","route":"/trials/nct06906341/"},{"id":"nct04421963","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib","route":"/trials/nct04421963/"},{"id":"rosella","kind":"trial","name":"ROSELLA / GOG-3073","route":"/trials/rosella/"},{"id":"nct00377429","kind":"trial","name":"Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy","route":"/trials/nct00377429/"},{"id":"nct06334432","kind":"trial","name":"Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors","route":"/trials/nct06334432/"},{"id":"nct06394492","kind":"trial","name":"SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","route":"/trials/nct06394492/"},{"id":"nct00716976","kind":"trial","name":"Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy","route":"/trials/nct00716976/"},{"id":"solo-1","kind":"trial","name":"SOLO-1","route":"/trials/solo-1/"},{"id":"soraya","kind":"trial","name":"SORAYA","route":"/trials/soraya/"},{"id":"nct04180371","kind":"trial","name":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","route":"/trials/nct04180371/"},{"id":"nct04561362","kind":"trial","name":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","route":"/trials/nct04561362/"},{"id":"nct06380660","kind":"trial","name":"Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors","route":"/trials/nct06380660/"},{"id":"nct03836352","kind":"trial","name":"Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur","route":"/trials/nct03836352/"},{"id":"nct05867251","kind":"trial","name":"Study of AVZO-021 in Patients With Advanced Solid Tumors","route":"/trials/nct05867251/"},{"id":"nct04644068","kind":"trial","name":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","route":"/trials/nct04644068/"},{"id":"nct05489211","kind":"trial","name":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","route":"/trials/nct05489211/"},{"id":"nct06834672","kind":"trial","name":"Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","route":"/trials/nct06834672/"},{"id":"nct03393884","kind":"trial","name":"Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)","route":"/trials/nct03393884/"},{"id":"nct04956640","kind":"trial","name":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","route":"/trials/nct04956640/"},{"id":"nct03564340","kind":"trial","name":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent","route":"/trials/nct03564340/"},{"id":"nct06819007","kind":"trial","name":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-","route":"/trials/nct06819007/"},{"id":"nct07736937","kind":"trial","name":"Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer","route":"/trials/nct07736937/"},{"id":"nct06799637","kind":"trial","name":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","route":"/trials/nct06799637/"},{"id":"nct05985655","kind":"trial","name":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","route":"/trials/nct05985655/"},{"id":"nct07225270","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re","route":"/trials/nct07225270/"},{"id":"nct07564141","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or","route":"/trials/nct07564141/"},{"id":"nct06619236","kind":"trial","name":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","route":"/trials/nct06619236/"},{"id":"nct01081951","kind":"trial","name":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax","route":"/trials/nct01081951/"},{"id":"nct07214779","kind":"trial","name":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","route":"/trials/nct07214779/"},{"id":"nct07219238","kind":"trial","name":"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o","route":"/trials/nct07219238/"},{"id":"nct07341100","kind":"trial","name":"Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC","route":"/trials/nct07341100/"},{"id":"nct04585750","kind":"trial","name":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","route":"/trials/nct04585750/"},{"id":"nct07109414","kind":"trial","name":"Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)","route":"/trials/nct07109414/"},{"id":"nct06618235","kind":"trial","name":"Trial of THEO-260 in Ovarian Cancer Patients","route":"/trials/nct06618235/"},{"id":"ukctocs","kind":"trial","name":"UKCTOCS","route":"/trials/ukctocs/"},{"id":"nct04644289","kind":"trial","name":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","route":"/trials/nct04644289/"},{"id":"nct06792435","kind":"trial","name":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","route":"/trials/nct06792435/"},{"id":"nct00390234","kind":"trial","name":"Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma","route":"/trials/nct00390234/"}],"person":[{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/"},{"id":"alan-dandrea","kind":"person","name":"Alan D. D'Andrea","route":"/people/alan-dandrea/"},{"id":"alberto-gabizon","kind":"person","name":"Alberto Gabizon","route":"/people/alberto-gabizon/"},{"id":"amit-oza","kind":"person","name":"Amit M. Oza","route":"/people/amit-oza/"},{"id":"andreas-du-bois","kind":"person","name":"Andreas du Bois","route":"/people/andreas-du-bois/"},{"id":"ane-gerda-eriksson","kind":"person","name":"Ane Gerda Eriksson","route":"/people/ane-gerda-eriksson/"},{"id":"angelina-jolie","kind":"person","name":"Angelina Jolie","route":"/people/angelina-jolie/"},{"id":"anna-fagotti","kind":"person","name":"Anna Fagotti","route":"/people/anna-fagotti/"},{"id":"anthony-goncalves","kind":"person","name":"Anthony Gonçalves","route":"/people/anthony-goncalves/"},{"id":"antonio-gonzalez-martin","kind":"person","name":"Antonio González-Martín","route":"/people/antonio-gonzalez-martin/"},{"id":"bradley-monk","kind":"person","name":"Bradley J. Monk","route":"/people/bradley-monk/"},{"id":"charlie-gourley","kind":"person","name":"Charlie Gourley","route":"/people/charlie-gourley/"},{"id":"christian-singer","kind":"person","name":"Christian Singer","route":"/people/christian-singer/"},{"id":"david-gershenson","kind":"person","name":"David M. Gershenson","route":"/people/david-gershenson/"},{"id":"domenica-lorusso","kind":"person","name":"Domenica Lorusso","route":"/people/domenica-lorusso/"},{"id":"douglas-levine","kind":"person","name":"Douglas A. Levine","route":"/people/douglas-levine/"},{"id":"eitan-friedman","kind":"person","name":"Eitan Friedman","route":"/people/eitan-friedman/"},{"id":"ephrat-levy-lahad","kind":"person","name":"Ephrat Levy-Lahad","route":"/people/ephrat-levy-lahad/"},{"id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","route":"/people/evanthia-galanis/"},{"id":"evelyn-lauder","kind":"person","name":"Evelyn Lauder","route":"/people/evelyn-lauder/"},{"id":"gilda-radner","kind":"person","name":"Gilda Radner","route":"/people/gilda-radner/"},{"id":"giovanni-scambia","kind":"person","name":"Giovanni Scambia","route":"/people/giovanni-scambia/"},{"id":"ignace-vergote","kind":"person","name":"Ignace Vergote","route":"/people/ignace-vergote/"},{"id":"isabelle-ray-coquard","kind":"person","name":"Isabelle Ray-Coquard","route":"/people/isabelle-ray-coquard/"},{"id":"jalid-sehouli","kind":"person","name":"Jalid Sehouli","route":"/people/jalid-sehouli/"},{"id":"james-brenton","kind":"person","name":"James Brenton","route":"/people/james-brenton/"},{"id":"jonathan-ledermann","kind":"person","name":"Jonathan A. Ledermann","route":"/people/jonathan-ledermann/"},{"id":"judy-garber","kind":"person","name":"Judy E. Garber","route":"/people/judy-garber/"},{"id":"yonemori-kan","kind":"person","name":"Kan Yonemori","route":"/people/yonemori-kan/"},{"id":"karen-lu","kind":"person","name":"Karen H. Lu","route":"/people/karen-lu/"},{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/"},{"id":"kunle-odunsi","kind":"person","name":"Kunle Odunsi","route":"/people/kunle-odunsi/"},{"id":"mansoor-raza-mirza","kind":"person","name":"Mansoor Raza Mirza","route":"/people/mansoor-raza-mirza/"},{"id":"mary-claire-king","kind":"person","name":"Mary-Claire King","route":"/people/mary-claire-king/"},{"id":"matthew-powell","kind":"person","name":"Matthew A. Powell","route":"/people/matthew-powell/"},{"id":"nicole-concin","kind":"person","name":"Nicole Concin","route":"/people/nicole-concin/"},{"id":"nicoletta-colombo","kind":"person","name":"Nicoletta Colombo","route":"/people/nicoletta-colombo/"},{"id":"rachel-michaelson-cohen","kind":"person","name":"Rachel Michaelson-Cohen","route":"/people/rachel-michaelson-cohen/"},{"id":"rita-schmutzler","kind":"person","name":"Rita Schmutzler","route":"/people/rita-schmutzler/"},{"id":"robert-coleman","kind":"person","name":"Robert L. Coleman","route":"/people/robert-coleman/"},{"id":"robert-mannel","kind":"person","name":"Robert S. Mannel","route":"/people/robert-mannel/"},{"id":"sara-brucker","kind":"person","name":"Sara Y. Brucker","route":"/people/sara-brucker/"},{"id":"sebastien-armanet","kind":"person","name":"Sébastien Armanet","route":"/people/sebastien-armanet/"},{"id":"shannon-westin","kind":"person","name":"Shannon N. Westin","route":"/people/shannon-westin/"},{"id":"gupta-sudeep","kind":"person","name":"Sudeep Gupta","route":"/people/gupta-sudeep/"},{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/"},{"id":"susana-banerjee","kind":"person","name":"Susana Banerjee","route":"/people/susana-banerjee/"},{"id":"thomas-herzog","kind":"person","name":"Thomas Herzog","route":"/people/thomas-herzog/"},{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","route":"/people/ursula-matulonis/"},{"id":"usha-menon","kind":"person","name":"Usha Menon","route":"/people/usha-menon/"},{"id":"willemien-van-driel","kind":"person","name":"Willemien J. van Driel","route":"/people/willemien-van-driel/"},{"id":"yechezkel-barenholz","kind":"person","name":"Yechezkel Barenholz","route":"/people/yechezkel-barenholz/"}],"paper":[{"id":"paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014","kind":"paper","name":"AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer","route":"/key-papers/paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014/"},{"id":"paper-gorski-brca1-founder-mutations-poland-ajhg-2000","kind":"paper","name":"Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer","route":"/key-papers/paper-gorski-brca1-founder-mutations-poland-ajhg-2000/"},{"id":"paper-body-fatness-iarc-nejm-2016","kind":"paper","name":"IARC verdict: excess body fat causes 13 cancers","route":"/key-papers/paper-body-fatness-iarc-nejm-2016/"},{"id":"paper-mujumdar-ivermectin-gynaecological-cancer-2025","kind":"paper","name":"Ivermectin and gynecologic cancer: what's the data?","route":"/key-papers/paper-mujumdar-ivermectin-gynaecological-cancer-2025/"},{"id":"paper-paola-1-nejm-2019","kind":"paper","name":"PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours","route":"/key-papers/paper-paola-1-nejm-2019/"},{"id":"paper-nhs-galleri-performance-nat-med-2026","kind":"paper","name":"Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial","route":"/key-papers/paper-nhs-galleri-performance-nat-med-2026/"},{"id":"paper-gabai-kapara-population-brca-screening-pnas-2014","kind":"paper","name":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","route":"/key-papers/paper-gabai-kapara-population-brca-screening-pnas-2014/"},{"id":"paper-brca-risk-reducing-surgery-jama-2010","kind":"paper","name":"PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers","route":"/key-papers/paper-brca-risk-reducing-surgery-jama-2010/"},{"id":"paper-slamon-her2-breast-ovarian-science-1989","kind":"paper","name":"Slamon 1989: HER2/neu in human breast and ovarian cancer","route":"/key-papers/paper-slamon-her2-breast-ovarian-science-1989/"},{"id":"paper-solo-1-nejm-2018","kind":"paper","name":"SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer","route":"/key-papers/paper-solo-1-nejm-2018/"},{"id":"paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997","kind":"paper","name":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews","route":"/key-papers/paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997/"}],"journal":[{"id":"international-journal-of-gynecological-cancer","kind":"journal","name":"International journal of gynecological cancer","route":"/journals/international-journal-of-gynecological-cancer/"},{"id":"journal-of-gynecologic-oncology","kind":"journal","name":"Journal of gynecologic oncology","route":"/journals/journal-of-gynecologic-oncology/"}],"institution":[{"id":"bc-cancer","kind":"institution","name":"BC Cancer","route":"/institutions/bc-cancer/"},{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","route":"/institutions/cruk-cambridge-centre/"},{"id":"chum","kind":"institution","name":"Centre hospitalier de l'Université de Montréal (CHUM)","route":"/institutions/chum/"},{"id":"centre-oscar-lambret","kind":"institution","name":"Centre Oscar Lambret","route":"/institutions/centre-oscar-lambret/"},{"id":"chris-obrien-lifehouse","kind":"institution","name":"Chris O'Brien Lifehouse","route":"/institutions/chris-obrien-lifehouse/"},{"id":"edinburgh-cancer-centre","kind":"institution","name":"Edinburgh Cancer Centre / CRUK Scotland Centre","route":"/institutions/edinburgh-cancer-centre/"},{"id":"esgo","kind":"institution","name":"European Society of Gynaecological Oncology","route":"/institutions/esgo/"},{"id":"hebrew-university-of-jerusalem","kind":"institution","name":"Hebrew University of Jerusalem","route":"/institutions/hebrew-university-of-jerusalem/"},{"id":"institut-bergonie","kind":"institution","name":"Institut Bergonié","route":"/institutions/institut-bergonie/"},{"id":"ipo-porto","kind":"institution","name":"Instituto Português de Oncologia do Porto Francisco Gentil","route":"/institutions/ipo-porto/"},{"id":"regina-elena-rome","kind":"institution","name":"IRCCS Regina Elena National Cancer Institute","route":"/institutions/regina-elena-rome/"},{"id":"kliniken-essen-mitte","kind":"institution","name":"Kliniken Essen-Mitte","route":"/institutions/kliniken-essen-mitte/"},{"id":"chuv-lausanne","kind":"institution","name":"Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne","route":"/institutions/chuv-lausanne/"},{"id":"newcastle-cancer-centre","kind":"institution","name":"Newcastle Cancer Centre / Northern Centre for Cancer Care","route":"/institutions/newcastle-cancer-centre/"},{"id":"northwell-cancer-institute","kind":"institution","name":"Northwell Health Cancer Institute","route":"/institutions/northwell-cancer-institute/"},{"id":"oneal-uab","kind":"institution","name":"O'Neal Comprehensive Cancer Center at UAB","route":"/institutions/oneal-uab/"},{"id":"oicr","kind":"institution","name":"Ontario Institute for Cancer Research","route":"/institutions/oicr/"},{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","route":"/institutions/oxford-cancer/"},{"id":"pumch","kind":"institution","name":"Peking Union Medical College Hospital","route":"/institutions/pumch/"},{"id":"gemelli","kind":"institution","name":"Policlinico Universitario A. Gemelli","route":"/institutions/gemelli/"},{"id":"qimr-berghofer","kind":"institution","name":"QIMR Berghofer Medical Research Institute","route":"/institutions/qimr-berghofer/"},{"id":"shaare-zedek","kind":"institution","name":"Shaare Zedek Medical Center","route":"/institutions/shaare-zedek/"},{"id":"sgo","kind":"institution","name":"Society of Gynecologic Oncology","route":"/institutions/sgo/"},{"id":"stephenson-oklahoma","kind":"institution","name":"Stephenson Cancer Center, OU Health","route":"/institutions/stephenson-oklahoma/"},{"id":"us-oncology-network","kind":"institution","name":"The US Oncology Network / US Oncology Research","route":"/institutions/us-oncology-network/"},{"id":"wistar","kind":"institution","name":"The Wistar Institute","route":"/institutions/wistar/"},{"id":"tongji-hospital-wuhan","kind":"institution","name":"Tongji Hospital, Huazhong University of Science and Technology","route":"/institutions/tongji-hospital-wuhan/"},{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","route":"/institutions/usb-basel/"},{"id":"uz-leuven","kind":"institution","name":"UZ Leuven / Leuven Cancer Institute","route":"/institutions/uz-leuven/"}],"bottleneck":[{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/"},{"id":"b-tme-immunosuppression","kind":"bottleneck","name":"Cold tumours and the immunosuppressive microenvironment","route":"/bottlenecks/b-tme-immunosuppression/"},{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/"},{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/"}],"biomarker":[{"id":"folr1-expression","kind":"biomarker","name":"Folate receptor alpha expression (FRα-positive, PS2+ >= 75%)","route":"/biomarkers/folr1-expression/"},{"id":"brca-germline","kind":"biomarker","name":"Germline BRCA1/2 pathogenic variant (gBRCAm)","route":"/biomarkers/brca-germline/"},{"id":"hrd-positive","kind":"biomarker","name":"HRD-positive (genomic instability score)","route":"/biomarkers/hrd-positive/"},{"id":"pd-l1-cps","kind":"biomarker","name":"PD-L1 CPS (combined positive score)","route":"/biomarkers/pd-l1-cps/"},{"id":"tp53-del17p","kind":"biomarker","name":"TP53 mutation and del(17p)","route":"/biomarkers/tp53-del17p/"},{"id":"brca-somatic","kind":"biomarker","name":"Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations","route":"/biomarkers/brca-somatic/"}]}}